These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1286154)

  • 1. Potential therapeutic targets in multistep oncogenesis.
    Burns PA; Balmain A
    Semin Cancer Biol; 1992 Dec; 3(6):335-41. PubMed ID: 1286154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenesis by mutations in anti-oncogenes: a view.
    Den Otter W; Koten JW; Van der Vegt BJ; Beemer FA; Boxma OJ; Derkinderen DJ; De Graaf PW; Huber J; Lips CJ; Roholl PJ
    Anticancer Res; 1990; 10(2B):475-87. PubMed ID: 2190526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are critical normal gene products in cancer cells the real therapeutic targets?
    Warenius HM
    Anticancer Res; 2002; 22(5):2651-5. PubMed ID: 12529977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targets for treatment success.
    Simon R
    Nat Clin Pract Oncol; 2006 Jan; 3(1):1. PubMed ID: 16407857
    [No Abstract]   [Full Text] [Related]  

  • 5. Mechanisms of translational deregulation in human tumors and therapeutic intervention strategies.
    Bilanges B; Stokoe D
    Oncogene; 2007 Sep; 26(41):5973-90. PubMed ID: 17404576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular oncogenes and cancer.
    Cooper GM
    Clin Physiol Biochem; 1987; 5(3-4):122-9. PubMed ID: 3621795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highlights in experimental therapeutics.
    Burger AM
    Cancer Lett; 2007 Jan; 245(1-2):11-21. PubMed ID: 16647200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular basis of cisplatin resistance in human carcinomas: model systems and patients.
    Scanlon KJ; Kashani-Sabet M; Miyachi H; Sowers LC; Rossi J
    Anticancer Res; 1989; 9(5):1301-12. PubMed ID: 2686531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carcinogenesis and the response of tumours to anticancer drugs.
    Keith WN; Brown R
    Anticancer Res; 1991; 11(5):1739-43. PubMed ID: 1768046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant p53: the loaded gun.
    Selivanova G
    Curr Opin Investig Drugs; 2001 Aug; 2(8):1136-41. PubMed ID: 11892926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amplification of cellular oncogenes in cancer cells.
    Alitalo K
    Med Biol; 1984; 62(6):304-17. PubMed ID: 6398390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenes: targets for immunodiagnosis and chemotherapy?
    O'Connor TE
    Prog Clin Biol Res; 1985; 172A():467-87. PubMed ID: 3991692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential of oncogene products as tumour markers.
    Chan S; Sikora K
    Cancer Surv; 1987; 6(2):185-207. PubMed ID: 3322544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic pathways of two types of gastric cancer.
    Tahara E
    IARC Sci Publ; 2004; (157):327-49. PubMed ID: 15055305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance.
    Zhu Y; Hu J; Hu Y; Liu W
    Cancer Treat Rev; 2009 Nov; 35(7):590-6. PubMed ID: 19635647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.
    Buettner R; Mora LB; Jove R
    Clin Cancer Res; 2002 Apr; 8(4):945-54. PubMed ID: 11948098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear hormone receptor variants: their role in malignancy and progression to hormone resistance in cancer.
    Sluyser M
    Acta Endocrinol (Copenh); 1991; 125 Suppl 1():48-53. PubMed ID: 1666242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker.
    Teodoridis JM; Strathdee G; Brown R
    Drug Resist Updat; 2004; 7(4-5):267-78. PubMed ID: 15533764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Oncogenes as indicators of occupational exposure to carcinogenic agents].
    Castoldi AF; Costa LG; Manzo L
    G Ital Med Lav; 1993; 15(1-4):45-50. PubMed ID: 7720962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.